| | | | | | | | | | |
|
|
| Dockets Entered
On May 16, 2005
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1977N-0316
|
| TETRACYCLINE (CHLORTETRACYCLINE & OXYTETRACYCLINE)PREMIXE
|
|
|
| 1980N-0208
|
| Biological Products; Bacterial Vaccines and Toxiods
|
|
|
| 1997S-0163
|
| Dietary Supplements, Courtesy Letters (Letters of Objection)
|
|
|
| 2002P-0312
|
| Periostat (doxycycline hyclate) 20 mg Capsules
|
|
|
| 2002P-0367
|
| Doxycycline hyclate capsules 20mg,Periostat capsules,20mg
|
|
|
| 2005N-0077
|
| Color Additive Certification; Increase in Fees for Certification Services
|
|
|
| 2005P-0187
|
| Amend 21 CFR 177.2280 pertaining to Liquid Epoxy Resin to remove phenyl glycidyl ether as a permissible constitutent.
|
|
|
| 2005V-0188
|
| Laser Light Show
|
|
|
| 1977N-0316
|
| TETRACYCLINE (CHLORTETRACYCLINE & OXYTETRACYCLINE)PREMIXE
|
|
|
| ANS
4
|
| HFV-200
|
| Vol #:
|
| 20
|
|
|
| ANS
5
|
| HFV-200
|
| Vol #:
|
| 20
|
|
|
| ANS
6
|
| HFV-200
|
| Vol #:
|
| 20
|
|
|
| 1980N-0208
|
| Biological Products; Bacterial Vaccines and Toxiods
|
|
|
| SUP 1
|
| McGuireWoods, LLP
|
| Vol #:
|
| 157
|
|
|
| 1997S-0163
|
| Dietary Supplements, Courtesy Letters (Letters of Objection)
|
|
|
| LET
823
|
| HFS-800 to World Nutrition, Inc
|
| Vol #:
|
| 25
|
|
|
| LET
824
|
| HFS-800 to Anabolic Laboratories Inc
|
| Vol #:
|
| 25
|
|
|
| LET
825
|
| HFS-800 to KneeLife LLC
|
| Vol #:
|
| 25
|
|
|
| LET
826
|
| HFS-800 to InteMedical LLC
|
| Vol #:
|
| 25
|
|
|
| LET
827
|
| HFS-800 to Inverness Medical Nutritional Group
|
| Vol #:
|
| 25
|
|
|
| LET
828
|
| HFS-800 to MD Drinks Inc
|
| Vol #:
|
| 25
|
|
|
| 2002P-0312
|
| Periostat (doxycycline hyclate) 20 mg Capsules
|
|
|
| LET
2
|
| HFA-305 to CollaGenex Pharmaceuticals, Inc.
|
| Vol #:
|
| 1
|
|
|
| LET
3
|
| HFA-305 to West-ward Pharmaceutical Corporation
|
| Vol #:
|
| 1
|
|
|
| NWL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2002P-0367
|
| Doxycycline hyclate capsules 20mg,Periostat capsules,20mg
|
|
| LET
2
|
| HFA-305 to CollaGenex Pharmaceuticals, Inc.
|
| Vol #:
|
| 1
|
|
|
| LET
3
|
| HFA-305 to West-ward Pharmaceutical Corporation
|
| Vol #:
|
| 1
|
|
|
| NWL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2005N-0077
|
| Color Additive Certification; Increase in Fees for Certification Services
|
|
|
| BKG
1
|
| Background Material
|
| Vol #:
|
| 1
|
|
|
| 2005P-0187
|
| Amend 21 CFR 177.2280 pertaining to Liquid Epoxy Resin to remove phenyl glycidyl ether as a permissible constitutent.
|
|